Who Generates Higher Gross Profit? Vertex Pharmaceuticals Incorporated or Grifols, S.A.

Vertex Pharmaceuticals leads in gross profit growth over Grifols.

__timestampGrifols, S.A.Vertex Pharmaceuticals Incorporated
Wednesday, January 1, 20141699214000519428000
Thursday, January 1, 20151930998000906794000
Friday, January 1, 201619122910001491717000
Sunday, January 1, 201721520110002213533000
Monday, January 1, 201820495600002638058000
Tuesday, January 1, 201923412320003615063000
Wednesday, January 1, 202022551650005469383000
Friday, January 1, 202119625960006670200000
Saturday, January 1, 202222315300007850400000
Sunday, January 1, 202323227010008607000000
Monday, January 1, 20249489600000
Loading chart...

Unlocking the unknown

Vertex Pharmaceuticals vs. Grifols: A Decade of Gross Profit Growth

In the competitive landscape of the pharmaceutical industry, Vertex Pharmaceuticals Incorporated and Grifols, S.A. have showcased remarkable financial trajectories over the past decade. From 2014 to 2023, Vertex Pharmaceuticals has consistently outperformed Grifols in terms of gross profit, with a staggering increase of over 1,500% from 2014 to 2023. In contrast, Grifols experienced a more modest growth of approximately 37% during the same period.

Key Insights

  • Vertex Pharmaceuticals: Starting with a gross profit of $519 million in 2014, Vertex's financial prowess surged to an impressive $8.6 billion by 2023, reflecting its strategic advancements and market expansion.
  • Grifols, S.A.: Despite a steady increase, Grifols' gross profit grew from $1.7 billion in 2014 to $2.3 billion in 2023, highlighting its stable yet slower growth trajectory.

This data underscores the dynamic shifts in the pharmaceutical sector, with Vertex Pharmaceuticals leading the charge in innovation and profitability.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025